In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sysmex Inostics GmbH

Division of Sysmex Corp.

Latest From Sysmex Inostics GmbH

German Diabetes Stakeholders Like The New Talk On Strategy And Reimbursement, But Where's The Action?

The up-to-10 million diabetics in Germany could benefit from a more optimal combination of digital tools and conventional case to maintain glucose control, say local IVD companies. But the industry is still waiting on the promised National Diabetes Strategy, while the government talks about more reimbursement support for innovation.

Germany In Vitro Diagnostics

Liquid Biopsy In Oncology: An Increasingly Crowded Landscape

Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.

Cancer In Vitro Diagnostics

Diagnostics In 2015: Past Trends Coalesce, New Roads Open

The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.

Medical Device Business Strategies

Deal Watch: Lilly/Qiagen Tie-Up Leads Spate Of Cancer Diagnostic Partnerships

Bayer looks to augment Xofigo and its prostate cancer portfolio through development and commercialization pact with Orion around Phase III-ready asset once partnered with Endo. Meanwhile, Shire and arGEN-X expand a collaboration in which the latter’s antibody-discovery technologies are being used to discover potential candidates against targets chosen by Shire.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Contract Research, Toxicology Testing-CRO
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Inostics GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Sysmex Corp.
  • Senior Management
  • Hartmut Juhl, MD, PhD, CEO
    Frank Diehl, PhD, CSO & Mgr. Dir.
  • Contact Info
  • Sysmex Inostics GmbH
    Phone: (49) (0) 40 413383 90
    Falkenried 88
    Hamburg, D 20251